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Abstract
Background: Hepatitis B virus (HBV) was among the first virus known to be transmitted by blood and blood
productions. The objective of this study is to determine the trend of hepatitis B virus in blood donors.
Materials and methods: In this study 79274 blood donors were retrospectively evaluated for HBsAg. The donors
were selected using personal questionnaire, physical examination and testing blood before donation. Blood banks
records are used as source of information. The blood donors samples were analyzed for the presence of hepatitis B
surface antigen (HBsAg) by commercial available kits ELISA method, third generation (from Abbott laboratory,
Germany). A sample was considered as HBsAg positive when found twice repeatedly reactive. Reactive samples
were not confirmed with addition tests.
Results: In the evaluation data, we found out that from 79274 of the total healthy blood donors, 15983 were
voluntary donors, 52876 were family replacement donors and 10424 commercial blood donors. The prevalence of
HBsAg in blood donors was 7.9%. It was increased steadily from 5.9% in 1999 to 9.1% in 2006 and decreased in
7.9% in 2009. According to blood donors status the HBsAg prevalence was 10.5% in commercial blood donors,
8.1% in voluntary donors and 8.6% in family replacement donors. The prevalence of anti-HBc in blood donors was
59.1%.
Conclusion: The prevalence of HBsAg was lower in voluntary non remunerate blood donors than commercial
donors and family replacement blood donors. In FDs the prevalence was higher than VDs but lower than CDs. So,
it is important to encourage the voluntary blood donors to become regularly blood donors.
Background
Hepatitis B virus (HBV) was among the first virus
known to be transmitted by blood and blood products.
HBV infection from transfusions became rare after the
introduction of the HBsAg test in early 1970, but
remains one of the most common serious complications
of transfusion particularly in countries with high and
intermediate prevalence of HBV [1-4]. The residual
transmission risk of HBV through transfusion is higher
[5-8]. This is attributed to the interval between initial
HBV infection and the detection of hepatitis B surface
antigen (HBsAg), resulting in a long window phase dur-
ing which the virus is transmissible [9,10]. After the
implementation of HBsAg screening in the 1975s, there
have been no further measures in Albania to decrease
the residual risk of HBV transmission, other than
improving the sensitivity of the HBsAg assay. Develop-
ment of sensitive assays to detect HBV-DNA showed
that healthy HBsAg-negatived o n o r sw h oa r ea n t i - H B c
positive, may harbour an occult HBV infection and
maintain HBV-DNA sequences in their liver and blood,
thus representing potential sources of HBV transmission
[11,12]. Evaluation of data on the prevalence of HBV,
among blood donors permits an assessment of the
occurrence of infection in the blood donor population
and consequently the safety of the collected donations.
This study was performed to assess prevalence and
trends of the viral hepatitis B during last decade (2000-
2009 years), among blood donors in Tirana. Moreover,
in a pilot study, we also explored the prevalence of anti-
HBC among randomly selected HBsAg negative blood
donor samples. * Correspondence: dvjollca@yahoo.com
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In this study 79274 blood donors were retrospectively
evaluated for HBsAg. The donors were selected using
personal questionnaire, physical examination and testing
blood before donation (as Hb level, blood pressure,
body weight, temperature). Blood banks records are
used (personal donor sheet, donation’s records) as
source of information. A first time blood donors is a
donors who has donated blood for first time and only
once. A regular blood donors is donors who has
donated blood more than two time during one year.
In this study family replacement donors and voluntary
non remunerate blood donors are first time blood
donors. We haven’t regular blood donors from these
groups. Family replacement donors are donors who
have donated the same number of units of blood as of
patient’s requirements, despite the blood group. A friend
or family member of the recipient donates blood to
replace the stored blood used in a transfusion, ensuring
a consistent supply.
To define the prevalence of HBV infection the number
of positive donors for each years is divided by the total
number of donors for each years.
Laboratory testing
Tests for HBsAg
The blood donors samples were analyzed for the pre-
sence of hepatitis B surface antigen (HBsAg) by com-
mercial available kits (as was presented in table 1). A
sample was considered as HBsAg positive when found
twice repeatedly reactive. Reactive samples were not
confirmed with addition tests. All reactive donors were
rejected from further blood donations.
Tests for anti-HBc
The blood donor samples were analyzed for the pre-
s e n c eo fa n t i - H B cu s i n gt h i r d generation monoelisa kit
anti HBC plus (Bio - Rad) with sensitivity 0.5 U PEI/ml
for IgG dhe 8 U PEI/ml for IgM and specificity 99.91%
Results
A total of 79274 blood donors have donated blood dur-
ing 10 years. In the evaluation data, we found out that
from the total 79274 healthy blood donors, 15983 were
voluntary donors, 52876 were replacement donors and
10424 commercial blood donors. Table 2 shows the
number of blood donors who have donated blood dur-
ing 1999-2009 years. The number of blood donors was
progressively increased during the years from 5233 in
1999 to 14352 in 2009. The number of commercial
blood donors was decreased from 1714 in 1999 to 284
in 2009. The number of voluntary non remunerate
blood donors was increased from 1200 in 1999 to 3639
in 2009 donors and family replacement blood donors
from 2319 in 1999 to 10429 in 2009.
Table 3 shows the prevalence of HBsAg in blood
donors between 1999-2009 years. The HBsAg was
detected in 5933 blood donors out of 79274 blood
donors screened. The prevalence of HBsAg in blood
donors was 7.9%. It was increased steadily from 5.9% in
1999 to 9.1% in 2006 and decreased in 7.9% in 2009.
Table 4 shows the prevalence of HBsAg based on
donor’s status. HBsAg was detected in 60 first time
commercial blood donors out of 561 firs time commer-
cial blood donors tested (prevalence 10.5%); in 1298 first
time voluntary non remunerate blood donors out of
15983 first time voluntary non remunerate blood donors
voluntary tested (prevalence 8.1%); in 4543 family repla-
cement blood donors out of 52876 family replacement
blood donors tested (prevalence 8.6%).
Table 5 shows the prevalence of anti-HBc in blood
donors. Anti-HBc was detected in 133 blood donors out
of 225 blood donors tested (prevalence 59.1%).
Table 1 The HBsAg screening kits used 1999-2009
Years Screening kit Manufacture Sensitivity Method
1999 Auszyme Monoclonal HBsAg Quantum II ABBOT Ad 04 ng/ml, ay 0.7 ng/ml Manual
2000 Auszyme Monoclonal HBsAg Quantum II ABBOT Ad 04 ng/ml, ay 0.7 ng/ml Manual
2001 Auszyme Monoclonal HBsAg Quantum II ABBOT Ad 04 ng/ml, ay 0.7 ng/ml Manual
2002 Auszyme Monoclonal HBsAg Quantum II ABBOT Ad 04 ng/ml, ay 0.7 ng/ml Manual
2003 IMx ABBOT Ad 0.22 ng/ml Ay 0.17 ng/ml Semi automatic
2004 IMx ABBOT Ad 0.22 ng/ml Ay 0.17 ng/ml Semi automatic
2005 IMx ABBOT Ad 0.22 ng/ml Ay 0.17 ng/ml Semi automatic
2006 AxSYM HBsAg (MEIA) ABBOT Ad 0.15 ng/mL
Ay 0.12 ng/mL
≤0.5 ng/mL
automated
2007 AXSYM CMIA ABBOT 100% automated
2008 Architect ABBOT 100% fully automate
2009 Architect ABBOT 100% fully automate
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detected in 73 first time blood donors out of 103 blood
donors tested (prevalence 70.8%); in 60 regular blood
donors out of 122 blood donors tested (prevalence
49.1%).
Discussed
Viral Hepatitis, especially hepatitis B in Albania con-
tinues to be a public health problem because of Albania
is the highly endemic area for hepatitis B. In Albania
the prevalence of HBsAg is 19% and anti-HBc 62% [13].
The endemicity of hepatitis B is described by the preva-
lence of HBsAg in the general population of a defined
geographical area, and it varies considerably globally:
HBsAg prevalence’s of >8% are typical of highly endemic
areas [14-17]. One of the primary concerns of Health
Department is the need to suppress the spread of this
highly contagious. The national blood transfusion ser-
vice in Albania is only responsible body for collection,
processing, testing and distribution of blood and blood
products under supervision of Ministry of Health.
HBsAg screening of all blood donations was mandatory
in national level, since 1975. In present study we ana-
lyzed the profile of blood donors and estimated the pre-
valence of HBsAg. Traditionally paid donors
(commercial donors) were the main source of blood in
Albania. The first efforts for the voluntary blood dona-
tion began in 1994 with a cooperation between National
Blood Service and Red Cross. One of the most impor-
tant problems of blood transfusion service in Albania
has always been reliance on professional blood donors
(paid blood donors) that still exist even if has been
reduce significantly. According to the data used in this
study, in 1999 commercial blood donors composed
32.8% of blood donors versus 1.9% in 2009. During last
years blood donors profile has changed as result imple-
mentation of national strategy for blood safety, launched
in 2005. Exclusion of paid donors was achieved by
rejecting the paid donor for the first time. First time
commercial blood donors were prohibited since 2008.
This change resulted in a very high percentage of first
time blood donors from voluntary blood donors and
family replacement blood donors groups. During these
years family replacement blood donors constitute the
largest group of blood donors in Albania. Our data in
this study showed that 72.6% of blood donors were
family replacement blood donors(in 2009).
The first lines of defence protection to assure the
safety of blood for transfusion are rejected from dona-
tion the candidate of blood donors who are undergoing
acute infection. Careful history taking is very important
because the vast majority of infectious virus transmitted
by transfusion are those causing in apparent or sub clin-
ical infections in blood donors [18,19]. The prevalence
of HBsAg in blood donors population depends on some
Table 2 Blood donors during 1999-2009
Blood donors Years
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Total number
Voluntary donors No. 1200 1110 210 509 506 605 1369 2027 2330 2478 3639 15983
% 22.9 25.9 6 12.9 11.6 11.7 19.1 23.9 20.8 21.3 25.3
Family replacement donors No. 2319 1810 1965 2224 2774 3464 4877 5840 8403 8771 10429 52876
% 44.3 42.2 56 56.7 63.5 67.1 68.4 69.2 74.9 75.4 72.6
Commercial donors No. 1714 1365 1333 1199 1088 1091 891 584 493 382 284 10424
% 32.8 31.9 38 30.6 24.9 21.2 12.5 6.9 4.3 3.3 1.9
Total 5233 4285 3508 3923 4368 5160 7137 8451 11226 11631 14352 79274
Table 3 HBsAg distribution in blood donors during 1999-
2009
Years Total number of blood donors tested Positive blood
donors
No %
1999 5233 307 5.9
2000 4285 235 6.5
2001 3508 178 5.1
2002 3923 272 6.9
2003 4368 275 6.3
2004 5160 376 7.3
2005 7137 568 7.95
2006 8451 769 9.1
2007 11226 898 8
2008 11631 920 7.9
2009 14352 1135 7.9
Total 79274 5933 7.5
Table 4 Distribution of HBsAg based on donor status
Donor status Screened HBsAg
No No %
First time commercial donors 561 60 10.5
First time Voluntary blood donors 15983 1298 8.1
Family replacement blood donors 52876 4543 8,6
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tion, diagnose of hepatitis B infection and sensitivity of
screening test.
Our data (table 3/figure 1) showed the higher preva-
lence of HBsAg in blood donors, 7.9% (it ranging from
5.9% in 1999 to 7.9% in 2009) comparing with neighbor
countries. So, the prevalence of HBsAg in blood donors
population is 4,1% in Turkey, 0.4% in Greece, 4.2% in
Kosovo, 1.32% in Macedonia, 0.4% in Italy [20-25].
The higher prevalence of HBsAg in blood donors
reflects epidemiological situation of HBV in our country.
According to previous studies in different group of
Albanian population the prevalence of HBsAg were
respectively in military recruitment 13,2%, in students 8-
15.3% and pediatric aged 1.4 - 3.9% [26]. These data
show that in blood donors the HBsAg prevalence is
lower than general population because of pre-donation
selection of blood donors who are interviewed with
screening questionnaire.
As it is shown in the figure 1 there is an increase in
prevalence of HBsAg in our donor population during
years. This could be the result of the improved testing
method from manual to fully automated and sensitivity
of screening test(table 1) and with the constant increase
of first time blood donors mainly family blood donors.
According to donors status, the prevalence of HBsAg
was lower in voluntary non remunerate blood donors
than commercial donors and family replacement blood
donors. In family replacement blood donors, the preva-
lence was higher than voluntary blood donors but lower
than paid donors (figures 2). So, it is important to
encourage the voluntary blood donors to become regu-
larly blood donors. Screening the blood donors for anti-
HBc or HBV DNA has reduced the risk of transmition
of HVB infection by transfusion of blood and his pro-
ducts [27]. It is generally accepted that the diagnosis of
infection by HBV is based on the presence of the
HBsAg in the bloodstream [28]. However, screening of
blood donors for HBsAg does not totally eliminate the
risk of HBV infection through blood transfusion [29]
since the absence of this marker in the serum does not
exclude the presence of HBV DNA [30-33]. It is possible
that, donors with occult HBV infection, who lacked
detectable HBsAg but whose exposure to HBV infection
was indicated by a positive anti-HBc and HBV DNA,
are a potential source of HBV infection [34-36].
Our pilot study revealed that 133 of 225 (59.1%)
HBsAg negative blood donors were anti-HBc positive
and thus were exposed to HBV infection. The isolated
finding of anti-HBc antibody in HBsAg-negative subjects
was considered a marker of past exposure to HBV and
of resolved infection. Results obtain from deferent stu-
dies in blood donors has shown that HBV DNA was
detected in 1.6% to 38% of HBsAg negative/anti HBc
positive blood donors [34,27,37]. Thus these donors my
be the potential to transmit HBV through transfusion.
The absence of HBsAg in the blood of apparently
healthy individuals may not be sufficient to ensure lack
of circulating HBV. Blood containing anti-HBc with or
without detectable presence of HBsAg might be infec-
tious, therefore routine blood donor screening for anti-
HBc has been implemented in some countries resulting
in a decrease in the risk of post-transfusion HBV infec-
tion [38].
While anti-HBc-positive blood donor may be a poten-
tial source of HBV transmission, routine application of
anti-HBc screening is not feasible in Albania. Our find-
ings in random screening HBsAg negative blood donors
Table 5 Anti-HBc prevalence in blood donors
Donor status Screened Anti-HBc
No No %
Regular blood donors 122 60 49.1
First time blood donors 103 73 70.8
Total 225 133 59.1
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Figure 1 HBsAg prevalence in blood donors during 1999-2009 years.
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rates among HBsAg-negative blood donors in endemic
area when the prevalence of anti-HBc is over 57% [39].
In country with intermittent and low prevalence of
HBsAg, anti-HBc prevalence vary from, 0.56% in the Uni-
ted Kingdom, 0.84% in United States, 1.4% in Germany,
15.03% in Greece [10,34-38]. In our study the HBsAg
negative/anti-HBc positive donor population is carry out
in two blood donors groups, regular blood donors and
first time blood donors. The prevalence rate of anti-HBc
was higher in first time blood donors than regularly
donors. So, the establishment of a panel of regular blood
donors is very important in providing safe blood and
blood products. Anti-HBc screening of blood donations is
controversial and variably performed in different coun-
tries. Currently it is limited to areas where the seropreva-
lence of HBV is low (generally <2%), while it is not
performed in areas with a high HBV seroprevalence
because the impact of the deferral of anti-HBc-positive
donors is considered not sustainable. However, the preva-
lence of occult HBV infection is higher in areas in which
HBV infection itself is more frequent. The safety of this
measure is currently being debated [40-42]. Our study
underscores the increasing the HBsAg prevalence in our
donor population. This trend, suggest that routine anti-
HBc screening of blood donors could possibly prevent
some transfusion-transmitted HBV infections from blood
donors. However, usefulness of screening for anti-HBc in
addition to HBsAg detection and introduction of PCR
based screenings like NAT to improve the safety of the
blood supply in Albania deserves further analysis.
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